Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 101–200 of 786
Dragoni, F., Chiarotti, F., Iori, A. P., Rocca, U. L., & Cafolla, A. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0181-5 · Cited by 41
Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling
Watson, C. T., Saaid, H., Vedula, V., Cardenas, J. C., Henke, P. K., Nicoud, F., Xu, X. Y., Hunt, B. J., & Manning, K. B. (2023) · Annals of Biomedical Engineering · doi:10.1007/s10439-023-03390-z · Cited by 46
Couturaud, F., Pernod, G., Presles, É., Duhamel, E., Jégo, P., Provost, K., Pan‐Petesch, B., Sollier, C. B. D., Tromeur, C., Hoffmann, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.210971 · Cited by 47
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease: Lessons From the COMPASS Trial
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 45
Self-citationAlexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. (2021) · Cureus · doi:10.7759/cureus.18992 · Cited by 46
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 43
Prandoni, P., Ageno, W., Mumoli, N., Zanatta, N., Imberti, D., Visonà, A., Ciammaichella, M. M., Simioni, L., Cappelli, R., Bucherini, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.03.022 · Cited by 41
Self-citationEpigenetic Regulation of F2RL3 Associates With Myocardial Infarction and Platelet Function
Corbin, L. J., Taylor, A. E., White, S. J., Williams, C. M., Taylor, K., van den Bosch, M. T. J., Teasdale, J. E., Jones, M., Bond, M., Harper, M. T., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.318836 · Cited by 42
Wan, T., Rodger, M. A., Zeng, W., Robin, P., Righini, M., Kovacs, M. J., Tan, M., Carrier, M., Kahn, S. R., Wells, P. S., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.11.020 · Cited by 38
Self-citationThe Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Al-Samkari, H. T., & Connors, J. M. (2018) · Cancers · doi:10.3390/cancers10080271 · Cited by 41
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Siniscalchi, C., Quintavalla, R., Rocci, A., Riera‐Mestre, A., Trujillo‐Santos, J., Suriñach, J. M., Jara‐Palomares, L., Bikdeli, B., Moustafa, F., & Monréal, M. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.028 · Cited by 37
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Anticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Rivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
Self-citationBradbury, C. A., Fletcher, K., Sun, Y., Heneghan, C. J., Gardiner, C., Roalfe, A. K., Hardy, P., McCahon, D., Heritage, G., Shackleford, H., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16275 · Cited by 44
Diagnosis and Management of Pulmonary Embolism
Trott, T., & Bowman, J. (2022) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2022.05.008 · Cited by 48
Breadth of complications of long-term oral anticoagulant care
Ageno, W., & Donadini, M. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.432 · Cited by 40
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Self-citationVenous thromboembolism: A clinician update
Serhal, M., & Barnes, G. D. (2019) · Vascular Medicine · doi:10.1177/1358863x18821159 · Cited by 37
Pawar, A. M., Gagne, J. J., Gopalakrishnan, C., Iyer, G. S., Tesfaye, H., Brill, G. E., Chin, K., & Bykov, K. (2022) · JAMA · doi:10.1001/jama.2022.1920 · Cited by 34
Venous Thromboembolism in Heart Failure Patients
Goldhaber, S. Z. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.028 · Cited by 34
Tran, H. A., Merriman, E., Baker, R. I., Curnow, J. L., Young, L., Tan, C.-W., McRae, S. J., & Chunilal, S. D. (2025) · Internal Medicine Journal · doi:10.1111/imj.70103 · Cited by 34
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Extended Anticoagulation for VTE
Mai, V., Guay, C.-A., Perreault, L., Bonnet, S., Bertoletti, L., Lacasse, Y., Mainbourg, S., Lega, J., & Provencher, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.402 · Cited by 38
Kraaijpoel, N., Tritschler, T., Guillo, E., Girard, P., & Gal, G. L. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14570 · Cited by 33
McBane, R. D., Loprinzi, C. L., Ashrani, A. A., Lenz, C. J., Houghton, D. E., Zemla, T., Le‐Rademacher, J. G., & Wysokiński, W. E. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13338 · Cited by 33
Mwiza, J.-M., Lee, R. H., Paul, D. S., Holle, L. A., Cooley, B. C., Nieswandt, B., Schug, W. J., Kawano, T., Mackman, N., Wolberg, A. S., et al. (2022) · Blood · doi:10.1182/blood.2022015787 · Cited by 35
Stoyko, Y. M., Кириенко, А. И., Ilyukhin, Е. А., Lobastov, K. V., Chabbarov, R. G., Parikov, M. A., Khorev, N. G., Zolotukhin, I. A., Andriyashkin, V. V., Karpenko, A. A., et al. (2019) · Journal of Venous Disorders · doi:10.17116/flebo20191302178 · Cited by 32
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
Kupó, P., Szakács, Z., Solymár, M., Habon, T., Czopf, L., Haţegan, L., Csányi, B., Borbás, J., Tringer, A., Varga, G., et al. (2019) · Angiology · doi:10.1177/0003319719874255 · Cited by 35
Prandoni, P., Vedovetto, V., Ciammaichella, M. M., Bucherini, E., Corradini, S., Enea, I., Cosmi, B., Mumoli, N., Visonà, A., Barillari, G., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.002 · Cited by 36
Self-citationSafety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Thromboembolism in Older Adults
Gross, P. L., & Chan, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.470016 · Cited by 36
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 38
Self-citationDirect oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Heestermans, M., Salloum‐Asfar, S., Streef, T. J., Laghmani, E. H., Salvatori, D. C. F., Luken, B. M., Zeerleder, S. S., Spronk, H. M. H., Korporaal, S. J. A., Kirchhofer, D., et al. (2019) · Blood · doi:10.1182/blood-2018-06-853762 · Cited by 34
Role of the anticoagulant monitoring service in 2018: beyond warfarin
Clark, N. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.348 · Cited by 35
Let’s Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked
Albertsen, I. E., Piazza, G., & Goldhaber, S. Z. (2018) · Circulation · doi:10.1161/circulationaha.118.036548 · Cited by 31
Rosovsky, R. P., Kline-Rogers, E., Lake, L., Minichiello, T., Piazza, G., Ragheb, B., Waldron, B., Witt, D. M., & Moll, S. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.010 · Cited by 29
Robin, P., Pennec, R. L., Eddy, M., Sikora, L., Roux, P. L., Carrier, M., Couturaud, F., Tromeur, C., Planquette, B., Sanchez, O., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.030 · Cited by 32
Guerreiro, E. M., Kruglik, S. G., Swamy, S. K., Latysheva, N., Østerud, B., Guigner, J., Sureau, F., Bonneau, S., Kuzmin, A. N., Prasad, P. N., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.01.004 · Cited by 31
Antiplatelet agents for the treatment of deep venous thrombosis
Flumignan, C. D. Q., Nakano, L. C. U., Baptista-Silva, J. C., & Flumignan, R. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012369.pub2 · Cited by 40
Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants
Flieder, T., Weiser, M., Eller, T., Dittrich, M. T., von Bargen, K., Alban, S., Kühn, J., Knabbe, C., & Birschmann, I. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.009 · Cited by 29
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Self-citationDiretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia – 2024
Gualandro, D. M., Fornari, L. S., Caramelli, B., Abizaid, A., Gomes, B. R., Tavares, C. A. M., Fernandes, C. J. C. D. S., Polanczyk, C. A., Jardim, C., Vieira, C. L. Z., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240590 · Cited by 43
Risk of Intracranial Hemorrhage Associated With Direct Oral Anticoagulation vs Antiplatelet Therapy
Coyle, M., Lynch, A., Higgins, M., Costello, M. M., Judge, C. S., O'Donnell, M. J., & Reddin, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.49017 · Cited by 32
Huang, W., Singer, D. E., Wu, Y., Chiang, C., Weng, H., Lee, M., & Ovbiagele, B. I. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2215 · Cited by 29
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban
Jacobson‐Kelly, A. E., & Bannow, B. S. (2020) · Hematology · doi:10.1182/hematology.2020000166 · Cited by 28
Palareti, G., Poli, D., Ageno, W., Legnani, C., Antonucci, E., Bucherini, E., Testa, S., Paoletti, O., Chistolini, A., Serrao, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007973 · Cited by 30
Self-citationHosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.036 · Cited by 30
Christiansen, M., Grove, E. L., & Hvas, A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1726096 · Cited by 32
Yamashita, Y., Morimoto, T., Muraoka, N., Shioyama, W., Chatani, R., Shibata, T., Nishimoto, Y., Ogihara, Y., Doi, K., Oi, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072758 · Cited by 27
Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?
Konstantinides, S., & Meyer, G. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02340-0 · Cited by 33
Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
Weitz, J. I., Prandoni, P., & Verhamme, P. B. (2020) · TH Open · doi:10.1055/s-0040-1721735 · Cited by 35
Self-citationRivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
Ajmal, M., Friedman, J., Sipra, Q. U. A. R., & Lassar, T. A. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/8886210 · Cited by 34
Frenzel, L., Decaux, O., Macro, M., Belhadj‐Merzoug, K., Manier, S., Touzeau, C., Leleu, X. P., Frère, C., Lecompte, T., Perrot, A., et al. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.11.021 · Cited by 28
Platelets as Central Actors in Thrombosis—Reprising an Old Role and Defining a New Character
Stevens, H., & McFadyen, J. D. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1698829 · Cited by 31
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Raggam, R. B., Hafner, F., Avian, A., Hackl, G., Cvirn, G., Brodmann, M., Gary, T., & Rief, P. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607433 · Cited by 29
Ahmad, I., Sharma, S., Gupta, N., Rashid, Q., Abid, M., Ashraf, M. Z., & Jairajpuri, M. A. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.048 · Cited by 26
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Blood · doi:10.1182/blood-2018-05-848697 · Cited by 27
Kim, K., Yamashita, Y., Morimoto, T., Kitai, T., Yamane, T., Ehara, N., Kinoshita, M., Kaji, S., Amano, H., Takase, T., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692425 · Cited by 28
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
Ashton, V., Kerolus‐Georgi, S., & Moore, K. T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1838 · Cited by 34
How, J., Story, C. M., Ren, S., Neuberg, D. S., Rosovsky, R. P. G., Hobbs, G. S., & Connors, J. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00566-5 · Cited by 27
Keller, L., Marten, S., Hecker, J. S., Şahin, K., Tittl, L., & Beyer‐Westendorf, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.097 · Cited by 28
Self-citationRusso, A. V., Curtis, S. A., Balbuena-Merle, R. I., Wadia, R. J., Wong, E. Y.-M., & Chao, H. H. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0108-7 · Cited by 26
Diseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Minno, M. N. D. D., Calcaterra, I. L., Papa, A., Lupoli, R., Minno, A. D., Maniscalco, M., & Ambrosino, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.004 · Cited by 29
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Højen, A. A., Nielsen, P. B., Overvad, T. F., Albertsen, I. E., Klok, F. A., Rolving, N., Søgaard, M., & Ording, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195970 · Cited by 32
Liu, J., Pei, W., Yan, Y., & Kui, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58345-4 · Cited by 27
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020230 · Cited by 28
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
Latest Innovations in the Treatment of Venous Disease
Attaran, R. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040077 · Cited by 32
Wysokiński, W. E., Froehling, D. A., Houghton, D. E., McBane, R. D., Vlazny, D. T., Bott‐Kitslaar, D. M., Kuczmik, W., Sutkowska, K., Bator, K., Hodge, D. O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13471 · Cited by 25
Frei, A. N., Stalder, O., Limacher, A., Méan, M., Baumgartner, C., Rodondi, N., & Aujesky, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1726345 · Cited by 27
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
Liu, A., Naymagon, L., & Tremblay, D. A. (2022) · Cancers · doi:10.3390/cancers15010011 · Cited by 24
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
Sun, G., Wu, J., Wang, Q., Liang, Q., Jia, J., Cheng, K., Sun, G., & Wang, Z. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.11.029 · Cited by 27
Áinle, F. N., & Kevane, B. (2020) · Hematology · doi:10.1182/hematology.2020002268 · Cited by 27
Vázquez-Santiago, M., Vilalta, N., Cuevas, B., Murillo, J., Llobet, D., Macho, R., Pujol‐Moix, N., Carrasco, M., Mateo, J., Fontcuberta, J., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.012 · Cited by 28
Geersing, G., Hendriksen, J. M. T., Zuithoff, N. P. A., Roes, K. C. B., Oudega, R., Takada, T., Schutgens, R. E. G., & Moons, K. G. M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003142 · Cited by 24
Hu, B., Jiang, L., Tang, H., Hu, M., Yu, J., & Dai, Z. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02274-z · Cited by 24
Superficial phlebitis and thrombophlebitis
Redaktsiia (2021) · Journal of Venous Disorders · doi:10.17116/flebo202115031211 · Cited by 24
Okumura, Y., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., Mo, M., Kobayashi, T., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0636 · Cited by 27
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Self-citationManagement of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Linnemann, B., Beyer‐Westendorf, J., Espinola–Klein, C., Mühlberg, K. S., Müller, O. J., & Klamroth, R. (2024) · Hämostaseologie · doi:10.1055/a-2178-6574 · Cited by 32
Self-citationUse of direct oral anticoagulants in patients on immunomodulatory agents
Man, L. M.-W., Morris, A., Brown, J. T., Palkimas, S., & Davidson, K. M. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1534-9 · Cited by 22
Sun, H., Zhao, Q., Wang, Y., Lakin, R., Feng, H., Fan, X., Huiling, L., Gao, D., Liu, L., He, Y., et al. (2018) · Medicine · doi:10.1097/md.0000000000009670 · Cited by 22
Update on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
Spence, J. D. (2018) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2018-0024 · Cited by 24
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Valeriani, E., Porreca, E., Weitz, J. I., Schulman, S., Candeloro, M., & Nisio, M. D. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14807 · Cited by 26
Self-citationBromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
Treating cancer-associated venous thromboembolism: A practical approach
Cutsem, E. V., Mahé, I., Felip, E., Agnelli, G., Awada, A. H., Cohen, A. T., Falanga, A., Mandalà, M., Peeters, M., Tsoukalas, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114263 · Cited by 21
Self-citation
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.